Rheumatoid Arthritis | TreatmentTrends | US | 2014
TreatmentTrends®: Rheumatoid Arthritis 2014 (US) explores the use of conventional DMARDs as well as biologics or Xeljanz for the treatment of rheumatoid arthritis (RA). One hundred U.S. rheumatologists were surveyed to investigate current and anticipated use of biologics or Xeljanz, perceived strengths and weaknesses of key marketed RA products, sales force performances, and products in development.
Related Market Assessment Reports
Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus, described as deep vein thrombosis (DVT) or pulmonary embolism (PE), depending on the vein affected. Anticoagulants…
Report
Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult ADHD (US)
Attention-deficit / hyperactivity disorder (ADHD), a common childhood neurodevelopmental condition that can persist into adulthood, affects about 6% of U.S. adults, or approximately 15.5 million…
Report
Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)
Hyperkalemia is defined as a serum potassium level above 5.0 mEq/L. This report covers the management of chronic hyperkalemia through diuretic therapy, correcting metabolic acidosis when present,…
